| 前收市價 | 6.44 |
| 開市 | 6.38 |
| 買盤 | 6.36 x 100 |
| 賣出價 | 6.44 x 200 |
| 今日波幅 | 6.26 - 6.65 |
| 52 週波幅 | 1.57 - 8.19 |
| 成交量 | |
| 平均成交量 | 249,624 |
| 市值 | 276.99M |
| Beta 值 (5 年，每月) | 0.71 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.05 |
| 業績公佈日 | 無 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 12.50 |
ZacksAll You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksHow Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZacksWerewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
